Myasthenia Graves Research Group


MG Research

ECU-MG-302: A Phase III, Open-Label, Extension Trial of ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects with Refractory Generalized Myasthenia Gravis

Sponsor Alexion Pharmaceuticals, Inc.
Site-PI Michael Benatar, MD, PhD
Summary Trial ECU-MG-301, a phase III clinical trial, has been initiated to evaluate the safety and efficacy of eculizumab in the treatment of refractory gMG. The ECU-MG-302 extension trial is designed to provide the subjects who have participated in the ECU-MG-301 trial an opportunity to receive eculizumab and to collect clinical data that will provide long-term safety and efficacy information on eculizumab in subjects with refractory generalized myasthenia gravis. Study visits will be performed at the University of Miami and study participation will extend over a period of up to 4 years.
Eligibility criteria
  • Subjects who have completed the ECU-MG-301 trial.
  • No pregnancy or breast-feeding
Funding agency Alexion Pharmaceuticals, Inc.
Project manager Sara-Claude Michon
Contact information Email:
Phone: (305) 243-6481
Presentations / Publications